Cited 3 times in
Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김병극 | - |
dc.date.accessioned | 2023-04-27T00:46:17Z | - |
dc.date.available | 2023-04-27T00:46:17Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 1936-8798 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194125 | - |
dc.description.abstract | Background: Although there is a growing body of evidence that CYP2C19 genotyping can be beneficial when considering treatment with clopidogrel after percutaneous coronary intervention (PCI), whether a genotype-guided strategy can be generally adopted in routine practice remains unclear among East Asians. Objectives: This study sought to investigate long-term outcomes of patients undergoing clopidogrel-based antiplatelet therapy after drug-eluting stent (DES) implantation according to CYP2C19 genotypes. Methods: From the nationwide multicenter PTRG-DES (Platelet function and genoType-Related long-term proGnosis in DES-treated patients) consortium, patients who underwent CYP2C19 genotyping were selected and classified according to CYP2C19 loss-of-function allele: rapid metabolizers (RMs) or normal metabolizers (NMs) vs intermediate metabolizers (IMs) or poor metabolizers (PMs). The primary outcome was a composite of cardiac death, myocardial infarction, and stent thrombosis at 5 years after the index procedure. Results: Of 8,163 patients with CYP2C19 genotyping, 56.7% presented with acute coronary syndrome. There were 3,098 (37.9%) in the RM or NM group, 3,906 (47.9%) in the IM group, and 1,159 (14.2%) in the PM group. IMs or PMs were associated with an increased risk of 5-year primary outcome compared with RMs or NMs (HRadj: 1.42; 95% CI: 1.01-1.98; P = 0.041), and the effect was more pronounced in the first year (HRadj: 1.67; 95% CI: 1.10-2.55; P = 0.016). The prognostic implication of being an IM and PM was significant in acute coronary syndrome patients (HRadj: 1.88; 95% CI: 1.20-2.93; P = 0.005) but not in those with stable angina (HRadj: 0.92; 95% CI: 0.54-1.55; P = 0.751) (interaction P = 0.028). Conclusions: Among East Asians with clopidogrel-based antiplatelet therapy after DES implantation, CYP2C19 genotyping could stratify patients who were likely to have an increased risk of atherothrombotic events. (Platelet Function and genoType-Related Long-term progGosis in DES-treated Patients: A Consortium From Multi-centered Registries [PTRG-DES]; NCT04734028) © 2023 American College of Cardiology Foundation | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | JACC-CARDIOVASCULAR INTERVENTIONS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Acute Coronary Syndrome* / drug therapy | - |
dc.subject.MESH | Acute Coronary Syndrome* / therapy | - |
dc.subject.MESH | Clopidogrel / adverse effects | - |
dc.subject.MESH | Cytochrome P-450 CYP2C19 / genetics | - |
dc.subject.MESH | Drug-Eluting Stents* | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Percutaneous Coronary Intervention* / adverse effects | - |
dc.subject.MESH | Platelet Aggregation Inhibitors / adverse effects | - |
dc.subject.MESH | Ticlopidine / adverse effects | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seung Hun Lee | - |
dc.contributor.googleauthor | Young-Hoon Jeong | - |
dc.contributor.googleauthor | David Hong | - |
dc.contributor.googleauthor | Ki Hong Choi | - |
dc.contributor.googleauthor | Joo Myung Lee | - |
dc.contributor.googleauthor | Taek Kyu Park | - |
dc.contributor.googleauthor | Jeong Hoon Yang | - |
dc.contributor.googleauthor | Joo-Yong Hahn | - |
dc.contributor.googleauthor | Seung-Hyuck Choi | - |
dc.contributor.googleauthor | Hyeon-Cheol Gwon | - |
dc.contributor.googleauthor | Myung Ho Jeong | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Hyung Joon Joo | - |
dc.contributor.googleauthor | Kiyuk Chang | - |
dc.contributor.googleauthor | Yongwhi Park | - |
dc.contributor.googleauthor | Sung Gyun Ahn | - |
dc.contributor.googleauthor | Jung-Won Suh | - |
dc.contributor.googleauthor | Sang Yeub Lee | - |
dc.contributor.googleauthor | Jung Rae Cho | - |
dc.contributor.googleauthor | Ae-Young Her | - |
dc.contributor.googleauthor | Hyo-Soo Kim | - |
dc.contributor.googleauthor | Moo Hyun Kim | - |
dc.contributor.googleauthor | Do-Sun Lim | - |
dc.contributor.googleauthor | Eun-Seok Shin | - |
dc.contributor.googleauthor | Young Bin Song | - |
dc.identifier.doi | 10.1016/j.jcin.2023.01.363 | - |
dc.contributor.localId | A00493 | - |
dc.relation.journalcode | J01193 | - |
dc.identifier.eissn | 1876-7605 | - |
dc.identifier.pmid | 37045504 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1936879823004120 | - |
dc.subject.keyword | CYP2C19 genotype | - |
dc.subject.keyword | clopidogrel | - |
dc.subject.keyword | drug-eluting stent(s) | - |
dc.subject.keyword | percutaneous coronary intervention | - |
dc.subject.keyword | prognosis | - |
dc.contributor.alternativeName | Kim, Byeong Keuk | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.citation.volume | 16 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 829 | - |
dc.citation.endPage | 843 | - |
dc.identifier.bibliographicCitation | JACC-CARDIOVASCULAR INTERVENTIONS, Vol.16(7) : 829-843, 2023-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.